Jiangsu Nhwa Pharmaceutical Co., LTD
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Jiangsu Enhua Pharmaceutical Co., Ltd. was founded in 1978 and listed on the Shenzhen Stock Exchange in 2008 with stock code 002262. It is a pharmaceutical enterprise that integrates science, industry, and trade. It is a designated national production unit for psychotropic drugs, a national high-tech enterprise, a national top 100 pharmaceutical enterprise, a national technological innovation demonstration enterprise, a national intellectual property demonstration unit, and a star unit of the national "20 years and 20 stars" pharmaceutical quality management enterprise, Vice President Unit of China Narcotics Association, Vice President Unit of Jiangsu Pharmaceutical Industry Association, One of the First Innovative Enterprises in Jiangsu Province, and Awarding Unit of Jiangsu Provincial Governor's Quality Award. The company mainly produces and operates central nervous system drugs, with a strategic positioning in the market of central nervous system drugs. It is mainly engaged in the development, production, and sales of central nervous system drugs. It is a company focused on the segmented market of central nervous system drugs, mainly in the categories of anesthesia, psychiatry, and neurology. Through years of unremitting efforts in product research and development, production, and service, The company has established a complete series of central nervous system drug products and marketing network, striving to become an important manufacturer and seller of central nervous system drugs in China. We have three large-scale modern pharmaceutical production bases for raw materials and pharmaceutical preparations, covering a total area of over 900 acres. The enterprise has workshops certified by the state for raw materials, solid preparations, water injection, freeze-dried powder injection, and more than ten automated production lines for tablets, capsules, water injection, and powder injection. According to the company's development strategy, we strive to focus on energy conservation and consumption reduction, environmental protection, and green development. We have passed the Energy Management System Certification (ISO50001) and International Environmental Certification (ISO14000), vigorously developed the export business of raw materials, and conducted international certifications such as the European Union, striving to gain a place in the international market. The company attaches great importance to technological innovation, emphasizes the development of new products, and strengthens the alliance between industry, academia, and research. The group's technology center is a nationally recognized enterprise technology center and a provincial-level engineering technology research center. It has enterprise academician workstations, national postdoctoral research workstations, postdoctoral innovation centers, and Jiangsu Provincial Key Laboratory for Central Nervous Drug Research, undertaking multiple national key research projects. |
| Headquarter | Xuzhou |
| Establish Date | 3/29/1999 |
| Listed Code | 002262.SZ |
| Listed Date | 7/23/2008 |
| Chairman | Sun Pengsheng. |
| CEO | Sun Jiaquan. |
| Website | www.nhwa-group.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
